Intravitreal injections are commonly used to deliver which type of therapy to the retina?

Intravitreal injections are commonly used to deliver which type of therapy to the retina?

• A. Anti-VEGF (Vascular Endothelial Growth Factor) injections
• B. Antibiotic injections
• C. Steroid injections
• D. Immunotherapy injections

Answer: (A)

Intravitreal injections deliver drugs directly into the vitreous humor to reach the retina, achieving high local concentrations while limiting systemic exposure. This route is ideal for therapies that need to act on retinal tissues quickly and precisely. Anti-VEGF therapy targets vascular endothelial growth factor, a key driver of abnormal blood vessel growth and fluid leakage in the retina. By inhibiting VEGF, these injections effectively reduce neovascularization and macular edema, making them the most common intravitreal treatment for conditions like wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusions. While antibiotics via this route are used for eye infections and steroids can help with inflammation and edema, anti-VEGF stands out as the standard option for chronic retinal diseases driven by VEGF activity. Immunotherapy injections are not a standard retina treatment delivered intravitreally.

Intravitreal injections deliver drugs directly into the vitreous humor to reach the retina, achieving high local concentrations while limiting systemic exposure. This route is ideal for therapies that need to act on retinal tissues quickly and precisely.

Anti-VEGF therapy targets vascular endothelial growth factor, a key driver of abnormal blood vessel growth and fluid leakage in the retina. By inhibiting VEGF, these injections effectively reduce neovascularization and macular edema, making them the most common intravitreal treatment for conditions like wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusions. While antibiotics via this route are used for eye infections and steroids can help with inflammation and edema, anti-VEGF stands out as the standard option for chronic retinal diseases driven by VEGF activity. Immunotherapy injections are not a standard retina treatment delivered intravitreally.